| Company Announcements: (reported by the Company) |
No items found
|
| Elevator Pitch: | Rhythm Biosciences is developing and commercialising Australian medical diagnostics technology for sale across national and international markets. Rhythm's lead product, ColoSTAT, is intended to provide the accurate and early detection of colorectal cancer, acting as either a 'first-step' screening test or within the triage of persons with a positive faecal immunochemical test (FIT) or colonoscopy. As well as being of value to those with risk factors associated with colorectal cancer, ColoSTAT provides an alternative for those who choose not to or are unable to be assessed using standard screening programs. |
| Category: | Hardware & devices |
| URL: | http://www.rhythmbio.com/ |
| Operational Status: | Active |
| ASX Listing Code (if applicable): | RHY |
| Year of Commencement: | 2017 |
| Address: | Melbourne |
| State: | Victoria |
| Overseas Operations: | No |
| Twitter: | |
| Facebook: | |
| Linkedin: | https://www.linkedin.com/company/rhythmbiosciences/ |
| Founders: | |
| Awards won: | |
